TLSA
Tiziana Life Sciences Ltd
NASDAQ · Healthcare · Biotechnology · GB
$1.02
+4.67%Aug 24, 2026, 12:49 UTC
Tiziana Life Sciences announced it will present Phase 2a BANYAN trial data for intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday.
Source:Jul 31, 2026, 17:32 UTC
Tiziana Life Sciences announced promising quantitative PET imaging results from the third patient in its Phase 2 clinical trial for a rare neurodegenerative condition, showing reduced neuroinflammation.
Source:Jun 25, 2026, 13:06 UTC
Tiziana Life Sciences dosed the last patient in its Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis.
Source: